Another is to build confidence in the process. The documents and testimony from agency and company officials will inform the discussion, which will culminate in a vote late Thursday afternoon. The FDA analysis supports a case that the Moderna vaccine should be authorized for emergency use, a quicker approach than the standard for full licensure. During the panel meeting about the Pfizer vaccine, the main sticking point was whether the evidence for use of the vaccine in 16- and 17-year-0lds was sufficient to include them in the population to get the vaccine. The vote 17-4, with one abstention, to recommend an EUA including those people reflected some doubts among a few of the experts that the evidence was adequate. Still, the solid majority vote paved the way for the agency to OK the vaccine, including for use in older adolescents. Authorization of Moderna's vaccine will be considered only for adults, so the meeting may go more smoothly. The agency acted day after the panel meeting for Pfizer's vaccine.